8-K: Abpro Holdings Faces Nasdaq Delisting Threat

Abpro Holdings, Inc. received multiple Nasdaq non-compliance notices regarding board and committee independence, prompting director appointments amid delisting concerns.

Summary

• Anthony D. Eisenberg resigned from the Board and all committees on January 28, 2026.
• Sooyoung Lee resigned from the Board and all committees on January 30, 2026.
• On February 5, 2026, Abpro Holdings received notice from Nasdaq regarding non-compliance with Listing Rule 5605(b)(1) (majority independent directors) and 5605(c)(2) (Audit Committee composition).
• The company is not eligible for the standard cure period for these deficiencies due to more than one vacancy, and the Nasdaq Hearings Panel will consider these issues for continued listing.
• A separate notice on February 5, 2026, indicated non-compliance with Nasdaq Listing Rule 5605(d)(2)(A) (Compensation Committee independence), for which a cure period is available until January 30, 2027, or July 29, 2026, depending on the next annual meeting.
• On February 9, 2026, the Board appointed M. Fatih Karatas and Mary Gunn as Class II directors, filling the two existing vacancies.
• Mr. Karatas and Ms. Gunn were appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to multiple Nasdaq non-compliance notices and the immediate threat of delisting proceedings, despite the company's efforts to appoint new directors.

Positives

• The Board has appointed two new directors, M. Fatih Karatas and Mary Gunn, to fill the existing vacancies.
• The new directors have been appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees, addressing some committee composition issues.
• The company has a cure period for the Compensation Committee non-compliance, extending until at least July 29, 2026, or January 30, 2027.
• The Nasdaq notices do not have an immediate effect on the listing of the company's common stock or warrants.

Negatives

• Two directors, Anthony D. Eisenberg and Sooyoung Lee, resigned from the Board and all committees.
• The company is non-compliant with Nasdaq Listing Rule 5605(b)(1) requiring a majority of independent directors.
• The company is non-compliant with Nasdaq Listing Rule 5605(c)(2) requiring the Audit Committee to consist of at least three independent directors.
• The company is not eligible for the standard cure period for the majority independent director and Audit Committee deficiencies due to multiple vacancies, making the situation more critical.
• The Nasdaq Hearings Panel will consider these deficiencies, posing a risk to continued listing.
• The company is non-compliant with Nasdaq Listing Rule 5605(d)(2)(A) regarding Compensation Committee independence.

Risks

• Inability to regain compliance with Nasdaq Listing Rules within required time periods.
• Potential delisting of the company's securities from The Nasdaq Capital Market.
• The Nasdaq Hearings Panel may not grant the company's request for continued listing.
• Forward-looking statements involve known and unknown risks, uncertainties, and assumptions which may cause actual results to differ materially from any results expressed or implied.

Future Outlook

The company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee who satisfy the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the applicable cure period. There can be no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing or that the company will be able to regain compliance with the applicable Nasdaq Listing Rules within the required time periods.

Management Comments

• The Board has initiated a process to identify and appoint qualified independent directors to fill the resulting vacancies and to satisfy the applicable requirements of The Nasdaq Stock Market (Nasdaq).
• The Company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee who satisfy the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the applicable cure period.
• The Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results.

Industry Context

StockSavvy.ai notes that maintaining compliance with exchange listing rules, particularly those related to board independence and committee composition, is a fundamental aspect of corporate governance for publicly traded companies. Failures in this area, while often company-specific, can signal broader governance weaknesses that may concern investors, irrespective of the company's operational performance or industry trends.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to uncertainty regarding continued Nasdaq listing and potential delisting. Governance concerns may affect investor confidence.
• Management/Employees: Increased pressure to resolve compliance issues and maintain listing.
• Regulatory Authorities: Nasdaq is actively monitoring and enforcing listing rules.

Next Steps

• The company must submit its views to the Nasdaq Hearings Panel in writing no later than February 12, 2026.
• The company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee prior to the expiration of the applicable cure period.
• The Nasdaq Hearings Panel will consider the deficiencies in connection with its determination regarding the company's continued listing.

Key Dates

Recommendation

The multiple Nasdaq non-compliance notices, particularly the ineligibility for a standard cure period for key board and audit committee independence rules, present a significant and immediate risk of delisting. While new directors have been appointed, the uncertainty surrounding the Nasdaq Hearings Panel's decision and the potential for delisting create substantial downside risk for investors. A seasoned investor would likely consider reducing exposure given the severe governance issues and the direct threat to the company's public trading status.

Keywords

Abpro Holdings, Nasdaq, Delisting, Corporate Governance, Board of Directors, Independent Directors, Audit Committee, Compensation Committee, Form 8-K, Compliance, ABP